Is Bayer a bargain stock despite the litigation surrounding Roundup?

The German chemicals group Bayer’s lawsuits over its Roundup weedkiller could throttle its profits. But is the gloom overdone? Matthew Partridge reports

“Only hours away” from another jury trial over its weedkiller Roundup, Germany’s Bayer has secured a postponement to allow room for “escalating settlement talks” to continue, reports Laura Kusisto and Ruth Bender in The Wall Street Journal. 

This has raised hopes that Bayer may be close to settling claims related to allegations that Roundup causes cancer, which have already caused Bayer to lose three individual cases, leaving it liable for a total of $190.5m in compensation. A fourth adverse verdict could have handed the 42,000 plaintiffs involved so far “additional ammunition in settlement talks that have dragged on for months”.

A settlement won’t come cheap, says Fortune. Experts believe that settling the “tens of thousands” of claims, which could eventually rise to as much as 85,000, could cost around $10bn, with some even putting the costs at $13bn. 

The lower estimate would imply $8bn to resolve current cases and $2bn set aside for future claims, including those related to diseases such as non-Hodgkin’s lymphoma “which can take years to diagnose”. There’s also the problem of trying to simultaneously negotiate with the various groups of plantiffs’ attorneys, “each with a sizable inventory of cases”.

The fact that Bayer’s shares rose by 4% on the news of the postponement suggests there is a risk that shareholders’ expectations “are getting carried away”, says Chris Hughes on Bloomberg. There remains a “real possibility” that the “saga” endures for longer than investors have anticipated if talks between the two sides break down. Indeed, given that Bayer still believes that Roundup doesn’t cause cancer, it could simply decide that it would be better off taking a chance on a trial if an acceptable figure cannot be reached.

The positive scenario

However, if a deal does end up being signed then shareholders could stand to do very well, as the chemical giant currently still trades at a “substantial discount” to its peers. The gap is worth “much more” than the settlement costs being discussed. 

Just getting to a valuation matching its cheapest counterparts “would add about €20bn of market value, after deducting the estimated cost of ending litigation”, while a move toward the average of its peer group would see the market value rise even higher.

Shareholders may be relieved at the “fairly modest” settlement, say Ed Cropley and Aimee Donnellan on Breakingviews. Still, they are still entitled to be “hopping mad” at the fact that Bayer got itself into the mess in the first place by buying Monsanto (which originally developed the drug) for $66bn in 2018. A Bayer investor who bought shares when the deal with Monsanto was completed would still have lost nearly 20% of their stake today, while those who invested in other drug companies would have made big profits. Bayer CEO Werner Baumann “has a lot of work to do” to ensure that Bayer’s shares close the gap.

Recommended

European stockmarkets will bounce back
European stockmarkets

European stockmarkets will bounce back

Last year was one to forget for European stockmarkets. But 2021 should prove better.
8 Jan 2021
Russia’s stockmarket is cheap for a very good reason
Emerging markets

Russia’s stockmarket is cheap for a very good reason

On a cyclically adjusted price/earnings ratio of just 7.3, Russia's stockmarket is in an entirely different value category to the rest of the world. A…
9 Apr 2021
Overlooked European stocks are a solid bargain
European stockmarkets

Overlooked European stocks are a solid bargain

The lack of speculative exuberance in European stocks compared to US markets bodes well for investors seeking less tech-heavy drama and more deep valu…
26 Mar 2021
Turkey heads for its next crisis after the lira plunges by 15%
Emerging markets

Turkey heads for its next crisis after the lira plunges by 15%

Turkey sacked its central bank governor after just four months in the job, sending the lira down by 15% against the dollar and stocks down by 9%.  
26 Mar 2021

Most Popular

How are my cryptocurrency gains taxed in the UK?
Bitcoin & crypto

How are my cryptocurrency gains taxed in the UK?

Many investors in cryptocurrencies have made big gains. But once you take profits – or even buy one cryptocurrency with another – you could be liable…
18 May 2021
US stocks look expensive – here’s what to own instead
Investment strategy

US stocks look expensive – here’s what to own instead

Right now, US stocks are among the most expensive in the world. So if you want a decent return on your investments, you should look into diversifying …
17 May 2021
We’re in another house price boom. How long will it last?
House prices

We’re in another house price boom. How long will it last?

UK house prices are in full-on boom mode again. And booms can last a lot longer than you might expect. John Stepek looks at what’s driving the current…
18 May 2021